[Nivolumab Treatment for the Patients with Gastric Cancer-Present and Future].

Abstract

Nivolumab, anti-PD-1 monoclonal antibody, has innovated treatment ofpatients with gastric cancer. Nivolmab has been indicated forBthird-line treatment ofgastric cancer patients in September 2017. Although it has been more than 1 year after nivolumab being widely used in practice, we still have many clinical questions in this population. We leverage evidence obtained from other types of cancer where we have more experience to use nivolumab to answer these questions step by step, but it is still far from enough with some complexities unique to gastric cancer. While nivolumab monotherapy has shown long term survival in some patients, more than halfofpatients experience disease progression right after treatment initiation with nivolumab. Because we have other treatment options, it is urgent to identify biomarkers to predict its efficacy. Now clinical trials ofimmune -checkpoint inhibitors in various treatment line are ongoing with translational research including biomarker analysis and we highly expect those outcome.

• Authors: Hiroshi Imazeki, Ken Kato, Narikazu Boku
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 46 Issue 10 Pg. 1513-1523 (Oct 2019) ISSN: 0385-0684 [Print] Japan
• PMID: 31631132 (Publication Type: Journal Article)

Chemical References

• Antibodies, Monoclonal
• Nivolumab

Topics

• Antibodies, Monoclonal
• Humans
• Nivolumab (therapeutic use)
• Stomach Neoplasms (drug therapy)